Dear Friend

Every 20 minutes, someone in Canada is diagnosed with colorectal cancer. Behind every diagnosis is a person, a family and a life changed. 

At Colorectal Cancer Canada, we work to ensure that people affected by this disease have access to the information, support and resources they need, while advocating for earlier detection and better outcomes. But we can’t do this work without the support of our community. 

This Giving Tuesday, we’re asking you to be part of something that matters. 

On December 1, we’ll launch our Every 20 Minutes campaign, sharing the voices and experiences of people whose lives have been touched by colorectal cancer. Their stories remind us that behind every statistic is a real person, and that support can make a meaningful difference. 

Your donation helps make this work possible. Together, we can provide information and support for patients and families, raise awareness, and advocate for the changes needed to improve outcomes for Canadians affected by colorectal cancer. 

This Giving Tuesday, help us make a difference. Because no one should have to face colorectal cancer alone.  

 On November 1, more than 200 participants took over the bowling tournament at Laurentian Lanes in Montreal for Strike Out Cancer, raising $50,0000 for Colorectal Cancer Canada — far surpassing the event's $20,000 goal!

Hosted by Jacqueline, Joseph and Michael in loving memory of their father, Harry Hopmeyer, 20 years after his passing, the morning brought family, friends and community together for bowling, laughter and connection — exactly the kind of moments Harry would have loved. Thank you to the Hopmeyer family, and to every participant, donor, sponsor and volunteer who made it such a success. 

Inspired to do the same? Strike Out Cancer is a community fundraiser created by a family, for a cause close to their hearts. You can create yours, too! Through our Community Events portal, you can turn a birthday, a sports event, a bake sale or a personal challenge into a fundraiser supporting CCC.

Children's Grief Awareness Day is Nov. 19

Grieving the loss or illness of a meaningful person is never easy, especially for children. Kids need support, understanding, and safe spaces to express their emotions at every step of their journey.

Our video series, Connecting Through Cancer: The Family Toolbox, offers practical guidance for parents and caregivers on how to talk to children about a diagnosis and support them throughout their emotional journey.

In this episode of Tush Talks, host Carl Bindman is joined by Janet Kreda for a rich discussion of her journey as a stage 3 anal cancer patient. They talk frankly about Janet’s diagnosis and treatment, the challenges she faced and the lessons she’s learned, and the crucial moment she got access to an experimental drug that changed her experience completely.

Signatera™ in Colorectal Cancer: From Evidence to Practice A webinar

How could Signatera™ fit into your colorectal cancer practice?

Colorectal Cancer Canada, in collaboration with Natera and LifeLabs, invites Canadian oncologists to a practical, case-based webinar connecting the latest international clinical trial evidence with the clinical and logistical questions that come up when considering ctDNA testing.

The session will explore:

Patient selection and timing: which patients and clinical settings to consider, and when testing may provide useful additional information

Interpreting and using results: assessing ctDNA findings alongside imaging, pathology and other clinical information, including evidence and limitations relevant to treatment and follow-up discussions

Speakers:

Robert Lentz, MD (Natera) and Mark Lewis, MD (Intermountain Health), moderated by Barry D. Stein, President and CEO, Colorectal Cancer Canada.

📅 November 20, 2026

🕑 2:00-3:00 pm EST

💻 Online | Free registration

Bring your clinical questions for the live Q&A. Register now and please share with your GI oncology colleagues and teams.

SUPPORT GROUPS

WHAT'S NEW IN RESEARCH?

Traditionally, treatment for stage II or III rectal cancer involves a combination of chemotherapy, radiation, and surgery, which can have significant short- and long-term impacts on patients' quality of life. The AZUR-1 trial is evaluating whether dostarlimab (Jemperli), an immunotherapy drug, can achieve durable responses without the need for these conventional treatments.